Lifecare ASA: Updated company presentation
Posted: 23/04/2025
Bergen, Norway, 23 April 2025 – Lifecare ASA (LIFE), a medtech company developing next generation continuous glucose monitoring (CGM) solutions for diabetes management, today publishes an updated company presentation articulating the company’s long-term value creation opportunity.
The presentation is attached and available at: https://lifecare.no/investor/
Key highlights from the presentation:
Diabetes is a trillion-dollar global healthcare challenge
- CGMs the fastest growing diabetes tech segment, representing a USD 30 billion market opportunity
- Within CGMs, implantable solutions represent a USD 5 billion potential market
Strong value drivers in place 2025-2028
- Set to capitalize on “second mover” advantage, leveraging first mover regulatory approvals in the US
- Capital efficient path to commercialization with partner-led go-to-market strategy and minimal additional R&D
- Near-term value inflection points including veterinary market launch late 2025, CE mark in 2026, and European human market launch in 2027
Significant value creation potential
- Peak revenue potential of USD 1 billion + on realistic market assumptions
- Revenue sustainable at high levels long-term assuming conservative market share in a growing market
- EBITDA margin of 35%+